A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Clinical trial NCT04456816 · RECRUITING

Trial details

NCT number: NCT04456816
Sponsor: SynAct Pharma Aps
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Severe Proteinuria Due to Idiopathic Membranous Nephropathy

Start date: 2020-08-31
Primary completion: 2026-06-30
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.